Mode
Text Size
Log in / Sign up
Phase 4 Completed N=27 Prevention

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

Spinal Cord Injuries · Postoperative Pain
Source: ClinicalTrials.gov NCT04256603 ↗
Enrolled (actual)
27
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcomePrimary: Neuropathic Pain — 13.3; 15.6 units on a scale — p=0.67
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a significant negative effect on quality of life. Efficacy of various treatments, however, remains controversial. There is evidence to support that gabapentin and pregabalin have some benefit in reducing neuropathic pain. Gabapentin is effective in the management of symptoms and concerns related to SCI including motor recovery, spasticity, and mood among others. This makes gabapentin an important pharmacologic intervention, which compels providers to define treatment guidelines related to its use. One aspect of which should relate to the timing of initiation of therapy. The goal of this study is to determine whether timing of initiation of treatment with gabapentin will decrease prevalence and intensity of neuropathic pain.

Outcome Measures

OutcomeResultp-value
PRIMARY
Neuropathic Pain
13.3; 15.6 0.67

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of acute spinal cord injury
  • Admission to acute inpatient rehabilitation

Exclusion Criteria

  • Unable to communicate verbally or by writing, unable to follow basic instructions, or unable to answer questions regarding their symptoms
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04256603). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search